Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 April 2021Website:
http://www.recursion.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 00:59:12 GMTDividend
Analysts recommendations
Institutional Ownership
RXRX Latest News
In an environment where the typical small biotech name is riskier than not, this one is curiously different.
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $6.40, representing a +1.27% change from its previous close.
This company stands to benefit from a shifting pharmaceutical industry landscape.
Recursion Pharmaceuticals (RXRX) reachead $6.36 at the closing of the latest trading day, reflecting a +0.47% change compared to its last close.
This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) , relating to its proposed merger with Exscientia PLC.
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.11, signifying a -0.97% move from its prior day's close.
Recursion said it was able to use its AI-enabled drug discovery platform to identify a novel target and move all the way to gaining IND approval in less than 18 months.
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $6.67, indicating a -1.91% shift from the previous trading day.
Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 results for one of its products.
What type of business is Recursion Pharmaceuticals?
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
What sector is Recursion Pharmaceuticals in?
Recursion Pharmaceuticals is in the Healthcare sector
What industry is Recursion Pharmaceuticals in?
Recursion Pharmaceuticals is in the Biotechnology industry
What country is Recursion Pharmaceuticals from?
Recursion Pharmaceuticals is headquartered in United States
When did Recursion Pharmaceuticals go public?
Recursion Pharmaceuticals initial public offering (IPO) was on 16 April 2021
What is Recursion Pharmaceuticals website?
https://www.recursion.com
Is Recursion Pharmaceuticals in the S&P 500?
No, Recursion Pharmaceuticals is not included in the S&P 500 index
Is Recursion Pharmaceuticals in the NASDAQ 100?
No, Recursion Pharmaceuticals is not included in the NASDAQ 100 index
Is Recursion Pharmaceuticals in the Dow Jones?
No, Recursion Pharmaceuticals is not included in the Dow Jones index
When was Recursion Pharmaceuticals the previous earnings report?
No data
When does Recursion Pharmaceuticals earnings report?
The next expected earnings date for Recursion Pharmaceuticals is 27 February 2025